Tumor Models

WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.

A large collection of cell line-derived xenograft (CDX) tumor models with an imaging based orthotopic/metastatic CDX platform covering 16 tumor types
Patient-derived xenograft (PDX) tumor models covering 20 cancer types, drug resistant model and mouse clinical trial enabling translational research
Syngeneic tumor models covering 20 cancer types, enabled with immunotherapy SOC, TIL analysis and RNAseq profiling.
Human immune checkpoint gene KI mouse models
hPBMC/HSC humanized models

Cell line-derived xenograft (CDX) tumor models

320+ validated models covering 30 tumor types
77+ cell lines derived from PDX models
Available data of sensitivities to SOC (standard of care)
Imaging-based orthotopic/metastatic tumor models
Brain/bone metastatic models of lung/breast cancer cell lines

41 Luciferase Labelled Orthotopic/Metastatic Tumor Models

Covering 17 tumor types
Bioluminescent imaging system in SPF barrier

tumor models, orthotopic models, luciferase, tumor types — *O: orthotopic model; M: metastatic model; S: validated with SOC; IC: intracranial model; Syngeneic models marked in red*

Patient-derived xenograft (PDX) tumor models

1,400+ PDX models covering full range of cancer types
Fully-characterized models with genetic, molecular and pharmacological profiling
Drug-resistant PDX models available
in vitro screening and derivative PDXC/PDXO models
IO-PDX panel with hPBMC humanization

PDX, patient-derived xenograft tumor models and drug-resistant models covering multiple cancer types

A Comprehensive PDX Collection of Asia Prevalent Tumors with Genomic Profiling

PDX, tumor models — *Profiled number marked in red*

Syngeneic tumor models

87 Syngeneic models (mouse, rat, hamster) covering 20 cancer types
Comprehensive panel of orthotopic syngeneic tumor models
Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
Tumor-infiltrating leukocytes (TILs) map
WES, RNA-seq and scRNA-seq characterization

Genetically engineered models

48 engineered cell lines based on construct overexpression or gene knock-in
Pharmacologically validated both in vitro and in vivo
Focusing on drug-resistant mutation introduction and IO-related checkpoint humanization
Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1

hPBMC/HSC Humanized Models

hPBMC Humanized Models

Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

Available humanized models from CIEA, combined with WuXi PDX/CDX models.
Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

Established CDX/PDX-hPBMC Models

hPBMC, tumor models — **Target efficacy validation*

Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study clinical grade checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system. WuXi Biology offers efficacy studies in different mouse strains with human targets KI in mice and cell line, and comprehensive flow cytometry to evaluate target expression and immune function.

Collection of various targets and background mouse strains
Validated with launched or most advanced clinical grade checkpoint antibodies
Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3)

human immune checkpoint gene KI knock-in mouse models to study checkpoint antibodies

Immuno-avatar humanized models

Mouse models harboring human tumor and human immune ceils
Three different diagram of hPBMC humanization for mature T cell engraftment
HSC (CD34+) avatar and next generation immune avatar for multiple-lineage engraftment (Myeloid, NK, DC)
IO-CDX and IO-PDX models with cancer targets and HLA information

Drug-resistant models

Engineered cell line derived xenograft models
Acquired drug-resistant CDX and PDX models
Intrinsic drug-resistant PDX models
Resistant models harboring specific oncogenic drivers
KRAS G12C drug resistant tumor models

Oncology and Immunology

Tumor Models

Tumor Models

Cell line-derived xenograft (CDX) tumor models

41 Luciferase Labelled Orthotopic/Metastatic Tumor Models

Patient-derived xenograft (PDX) tumor models

A Comprehensive PDX Collection of Asia Prevalent Tumors with Genomic Profiling

Syngeneic tumor models

Genetically engineered models

hPBMC/HSC Humanized Models

hPBMC Humanized Models

HSC Humanized Models

Established CDX/PDX-hPBMC Models

Human immune checkpoint gene KI mouse models

Immuno-avatar humanized models

Drug-resistant models

Related Resources View All